SADBE for Alopecia Areata
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a chemical called SADBE to help children and teens with hair loss grow their hair back. The treatment works by causing a small skin reaction that can wake up hair follicles. SADBE is known for its low side-effect profile and hair regrowth potential.
Will I have to stop taking my current medications?
The trial requires that participants be on a stable regimen of allowed medications, but some medications must be stopped before joining. For example, topical steroids must be stopped 2 weeks before, and certain immune suppressants and other treatments must be stopped 8 weeks before the study starts.
Is squaric acid dibutyl ester (SADBE) safe for treating alopecia areata?
How is the drug SADBE different from other treatments for alopecia areata?
SADBE is unique because it is a topical immunotherapy that works by causing a mild allergic reaction on the skin to stimulate hair regrowth, which is different from other treatments that might use steroids or other systemic medications. It is particularly used for patients who have not responded to conventional therapies, and its effectiveness can vary based on factors like the duration and severity of the disease.13456
What data supports the effectiveness of the treatment Squaric Acid Dibutyl Ester (SADBE) for alopecia areata?
Who Is on the Research Team?
Adelaide Hebert, MD
Principal Investigator
The University of Texas Health Science Center, Houston
Are You a Good Fit for This Trial?
This trial is for children and adolescents with alopecia areata who have experienced hair loss for less than 5 years and have more than 10% scalp hair loss without regrowth in the past 6 months. Participants must avoid UV light exposure, not be pregnant or breastfeeding, use contraception if applicable, and cannot have certain skin diseases, active infections, a history of significant psychiatric conditions or substance abuse.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either placebo or 5% SADBE for 12 months to evaluate efficacy and tolerability in treating alopecia areata
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Squaric Acid Dibutyl Ester
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas Health Science Center, Houston
Lead Sponsor